Eli Lilly Cuts 340B Drug Discounts for Non-Compliant Hospitals, Sparking Legal and Industry Backlash

Eli Lilly has begun terminating 340B drug discounts for approximately 50 hospitals that refused to provide claims data as required under its January policy, marking a sharp escalation in pharmaceutical manufacturer enforcement of the federal discount program. The move—announced after the company warned hospitals in May—follows a January directive demanding comprehensive claims data to prevent “duplicate discounts,” a claim disputed by hospital trade groups calling the action unlawful. With up to 1,000 hospitals non-compliant and 2,300 having submitted data, the policy shift threatens to disrupt drug pricing for safety-net hospitals reliant on the 340B program, which funds care for low-income and uninsured patients.

Key Clinical Takeaways:

• 50 hospitals lose 340B discounts: Eli Lilly is enforcing its January policy by cutting discounts for non-compliant hospitals, affecting systems that refused to submit claims data despite follow-up notices.
• 1,000+ hospitals still non-compliant: While 2,300 hospitals submitted data, up to 1,000 remain non-compliant, raising concerns about access to discounted drugs for safety-net providers.
• Legal and operational risks escalate: Hospital trade groups argue the move is unlawful, while Lilly frames it as necessary to prevent “duplicate discounts,” creating uncertainty for providers and patients.

Why Eli Lilly’s 340B Enforcement Threatens Safety-Net Hospitals

The 340B Drug Pricing Program, established by Congress in 1992, allows qualifying hospitals to purchase outpatient drugs at steep discounts—typically 20% to 50% below market rates—using those savings to expand care for uninsured or low-income patients. For hospitals serving Medicaid or Medicare populations, these discounts are critical: a 2023 HRSA report found that 340B savings enabled $1.2 billion in patient care expansions in 2022 alone. Yet Lilly’s policy—enforced after hospitals failed to comply with data requests—risks shrinking those savings by disqualifying non-compliant providers from the program.

Lilly’s action stems from a January announcement where the company alleged that some hospitals were receiving “duplicate discounts” by purchasing drugs at both 340B rates and through other federal programs. According to STAT+, Lilly cited internal audits showing discrepancies in claims data submission, prompting the company to demand comprehensive electronic records. “We’ve been clear that compliance is non-negotiable,” a Lilly spokesperson stated in May, adding that the policy would apply to hospitals that failed to respond to follow-up letters by June.

“This is a direct attack on the financial viability of safety-net hospitals,” said Dr. Sarah Chen, a health policy researcher at Johns Hopkins Bloomberg School of Public Health. “The 340B program is designed to ensure drugs reach patients who can’t afford them. If hospitals are penalized for administrative delays, it’s patients—not the pharmaceutical companies—who will bear the cost.”

How the Policy Contrasts with Past Enforcement—and What’s Next

Lilly’s approach differs from past 340B enforcement actions, where disputes typically centered on drug manufacturer compliance with the program’s rules rather than hospital data submission. In 2022, for example, the HRSA Office of Pharmacy Affairs issued fines to manufacturers for failing to provide discounts, but hospitals themselves were rarely penalized for data-related issues. This shift raises questions about whether Lilly’s policy sets a precedent for stricter manufacturer oversight—or whether it signals broader industry frustration with perceived “abuse” of the 340B program.

Hospital trade groups, including the American Hospital Association (AHA), have condemned Lilly’s move as unlawful, arguing that the company lacks authority to unilaterally revoke discounts. “This is not how the 340B program was designed to work,” said AHA spokesperson Mark Langel in a statement. “Hospitals are complying with federal requirements, and Lilly’s actions create unnecessary barriers to patient care.”

Legally, the dispute hinges on whether Lilly’s data requests fall under the 340B statute’s “audit” provisions, which allow manufacturers to review hospital claims for accuracy. The Affordable Care Act’s 340B amendments (2010) expanded manufacturer audit rights, but they do not explicitly grant manufacturers the power to terminate discounts for non-compliance. Legal experts suggest the issue may soon reach federal courts, where hospitals could challenge Lilly’s actions as arbitrary.

“The real risk here is that Lilly’s policy could trigger a domino effect,” warned Dr. Rajiv Mehta, a pharmaceutical economist at the University of Pennsylvania. “If other manufacturers follow suit, we could see a cascade of discounts being revoked, forcing hospitals to either cut services or pass costs onto patients—exactly what the 340B program was meant to prevent.”

Who Wins and Who Loses in This Policy Shift?

The immediate losers are likely to be the hospitals and patients most dependent on 340B discounts. A 2024 analysis by the Kaiser Family Foundation found that hospitals in rural and urban underserved areas derive 40% of their drug budgets from 340B savings. For these providers, losing access to discounted drugs could force painful choices: reducing staff, scaling back services, or—worst-case—closing entirely. Patients in these communities, many of whom are uninsured or underinsured, would face higher out-of-pocket costs or delayed treatments.

On the other hand, Lilly and other pharmaceutical manufacturers may argue that stricter enforcement is necessary to prevent “gaming” of the system. The company has pointed to cases where hospitals allegedly resold 340B drugs at market rates, undermining the program’s intent. However, critics note that Lilly’s policy fails to address the root cause: underfunding of the 340B program itself. Since its inception, the program has faced criticism for lacking sufficient oversight, leading to inconsistencies in how discounts are applied. A 2023 GAO report found that HRSA’s enforcement mechanisms were insufficient to prevent abuses, leaving manufacturers like Lilly to fill the gap—often unilaterally.

What This Means for Healthcare Providers—and How to Navigate Compliance Risks

For hospitals already struggling with financial pressures, Lilly’s policy adds another layer of uncertainty. Providers facing potential discount revocations should take immediate steps to ensure compliance with manufacturer data requests. This includes:

• Audit and reconcile claims data: Verify that all drug purchases are accurately reported to manufacturers, including those under 340B and other federal programs.
• Consult healthcare compliance attorneys: Specialized legal teams can help hospitals assess the legality of manufacturer demands and prepare for potential disputes. [For expert guidance on 340B compliance, consult Healthcare Compliance Lawyers, a directory of attorneys specializing in pharmaceutical pricing regulations.]
• Engage with pharmacy benefit managers (PBMs): Some PBMs offer tools to streamline claims reporting and reduce the risk of duplicate discounts. [Providers can explore partnerships with certified PBM consultants to optimize drug procurement strategies.]
• Advocate for legislative clarity: Hospital associations are pushing for Congress to intervene, but individual providers can also lobby state legislatures to address 340B funding gaps. [For policy advocacy support, connect with AHA’s state advocacy network, which provides tools for hospitals to engage with policymakers.]

For patients reliant on safety-net hospitals, the policy shift could lead to higher costs or reduced access to medications. Those affected should:

• Check insurance coverage: Some patients may qualify for additional subsidies or patient assistance programs if their hospital’s 340B discounts are revoked.
• Explore alternative clinics: Federally Qualified Health Centers (FQHCs) and rural health clinics often have similar funding structures and may offer lower-cost alternatives. [Use the HRSA Health Center Locator to find nearby providers.]
• Monitor legislative updates: Bills like the 340B Strengthening Act aim to reform the program, and patient advocacy groups are tracking progress. [For real-time updates, follow 340B Health, a nonprofit dedicated to program transparency.]

The Broader Impact: Will This Change Drug Pricing Forever?

Lilly’s move is unlikely to be an isolated incident. With pharmaceutical spending exceeding $600 billion annually in the U.S. and manufacturers facing pressure to control costs, other companies may adopt similar enforcement strategies. The question is whether this will lead to a more efficient 340B program—or a fragmented system where hospitals face arbitrary penalties for administrative oversights.

One potential outcome is increased collaboration between manufacturers and providers to standardize claims reporting. Lilly has already signaled openness to working with compliant hospitals to improve data transparency, suggesting that the company’s ultimate goal is not punishment but systemic reform. However, without federal intervention, the risk remains that hospitals—particularly smaller or under-resourced systems—will bear the brunt of enforcement actions.

As the debate unfolds, one thing is clear: the 340B program’s future hinges on balancing two competing priorities. On one side, manufacturers seek to prevent perceived abuses; on the other, hospitals and patients rely on the program to deliver affordable care. The coming months will determine whether Lilly’s policy becomes a model for stricter oversight—or a cautionary tale about the unintended consequences of pharmaceutical enforcement.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*